葡萄提取物(Entelon) - 在研适应症：骨关节炎，静脉功能不全_专利_临床

概要

基本信息

药物类型

中药

别名

Enteron、Vitis vinifera Seed Extract

靶点-

作用机制-

治疗领域

心血管疾病皮肤和肌肉骨骼疾病

在研适应症

骨关节炎静脉功能不全

非在研适应症

膝关节炎

原研机构

Hanlim Pharm Co., Ltd.

在研机构

Hanlim Pharm Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2011-01-01),

骨关节炎静脉功能不全

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与葡萄提取物相关的临床试验

NCT03962296 / Completed临床4期IIT

A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy

This was a multicentre, randomised, double-blind controlled study that compared the efficacy and safety of V. vinifera extract, calcium dobesilate (CD), and placebo in subjects with DME. Patients made 6 clinic visits, namely the screening visit; baseline visit (T0); and follow-up visits at 3 (T3), 6 (T6), 9 (T9), and 12 (T12) months.

开始日期2012-11-21

申办/合作机构

Hanyang University

[+1]

NCT01768520 / Completed临床3期

For 12 Weeks, the Multi-center, Randomized, Double-blinded, Clinical Study to Evaluate the Efficacy and Safety of Entelon Tab. 150mg Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee (Phase III)

This clinical trial is planned to prove Entelon tab. arm is not inferior to Celebrex cap. arm in terms of the efficacy and safety through the change of K-WOMAC's total score sum in patients with osteoarthritis of knee.

开始日期2012-07-02

申办/合作机构

Hanlim Pharm Co., Ltd.

100 项与葡萄提取物相关的临床结果

登录后查看更多信息

100 项与葡萄提取物相关的转化医学

登录后查看更多信息

100 项与葡萄提取物相关的专利（医药）

登录后查看更多信息

3

项与葡萄提取物相关的文献（医药）

2024-07-05·Medicine

Cross-sectional analysis for lymphedema epidemiology in South Korea by HIRA data: An observational study

Article

作者: Kim, Dong-Jin ; Yoon, Eul-Sik ; Yu, Yeonju ; Kim, Da-Som ; Chung, Jae-Ho

Lymphedema is known to affect as many as 140 to 250 million people worldwide. Approximately 99% of lymphedemas are secondary cases after lymphadenectomy, radiation, or parasite infection. There has been no accurate estimate of the lymphedema population size in South Korea. This study aimed to quantify the epidemiology of lymphedema in South Korea and analyze the clinical characteristics of patients with lymphedema using a nationwide database. This large-scale cross-sectional study included patients who received one of the following three diagnostic codes – Q82.0 (hereditary lymphedema), I97.2 (breast cancer-related lymphedema), and I89.0 (unclassified lymphedema) from the Korean Health Insurance Review and Assessment service between January 2019 and July 2022 at tertiary hospitals, general hospitals, or other hospitals. The demographics of the lymphedema population, medication use, and medical characteristics were identified. Over the last 4 years, the annual incidence of lymphedema has steadily increased and peaked in 2021 with the number 1.85 out of 1000. Of all patients, 81% were located in the upper extremity, and 10.6% had previous cancer. Most patients were diagnosed in general hospitals (53.2%), at orthopedic surgery department (41.9%). On average, lymphedema patients spent 70.17 US dollar for medication and hospitalized for 16.9 days annually after diagnosis. Commonly prescribed medications were Entelon® (Vitis vinifera seed extract) (66.9%), steroids (40.5%), non-steroidal anti-inflammatory drugs (26.5%) and diuretics (21.8%). Only 5.7% of patients received surgery and 19.2% received herbal medicine. This is the first study in South Korea to quantify demographic and medical characteristics of lymphedema patients. These results will contribute to a comprehensive understanding of lymphedema diagnosis and treatment in our nation.

2013-12-01·Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia4区 · 医学

Efficacy of food supplement to improve metabolic syndrome parameters in patients affected by moderate to severe psoriasis during anti-TNFα treatment.

4区 · 医学

Article

作者: Proietti, I ; Nicolucci, F ; Skroza, N ; Mancini, M T ; Pampena, R ; Soccodato, V ; Potenza, C ; Bernardini, N ; La Viola, G ; Tolino, E ; Zuber, S ; Balduzzi, V

AIMPsoriasis is a systemic inflammatory immune-mediated skin disease. Recently a relationship with metabolic syndrome in terms of psoriasis severity and response to therapy was observed.METHODSWe performed an open-label randomized controlled study to evaluate the role of a nutraceutical containing Q10 coenzyme, Krill-oil, lipoic acid, resveratrol, Vitis vinifera seed oil, vitamin E and selenium in addition to etanercept therapy for patients affected by psoriasis and metabolic syndrome. Forty patients were enrolled and divided into two arms, one receiving only etanercept, one other receiving also the neutraceutical. After a period of 3 months (T1) a second evaluation of the considered parameters was performed.RESULTSAt T1 statistically significant differences were detected in HDL cholesterol and triglycerides values both comparing the two arms and in the nutraceutical arm.CONCLUSIONOur results show that the dietary addiction of the nutraceutical to the etanercept therapy in patients affected by both psoriasis and metabolic syndrome could help to restore the normal lipid profile.

Molecules3区 · 化学

Entelon® (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells

3区 · 化学

ArticleOA

作者: You, Daeun ; Lo, Eunji ; Jeong, Yisun ; Kim, Sangmin ; Lee, Jeong Eon ; Kim, Seok Won ; Kim, Sung A ; Nam, Seok Jin ; Yoon, Sun Young

Interleukin-1 (IL1) is a proinflammatory cytokine and promotes cancer cell proliferation and invasiveness in a diversity of cancers, such as breast and colon cancer. Here, we focused on the pharmacological effect of Entelon® (ETL) on the tumorigenesis of triple-negative breast cancer (TNBC) cells by IL1-alpha (IL1A). IL1A enhanced the cell growth and invasiveness of TNBC cells. We observed that abnormal IL1A induction is related with the poor prognosis of TNBC patients. IL1A also increased a variety of chemokines such as CCL2 and IL8. Interestingly, IL1A expression was reduced by the ETL treatment. Here, we found that ETL significantly decreased the MEK/ERK signaling pathway in TNBC cells. IL1A expression was reduced by UO126. Lastly, we studied the effect of ETL on the metastatic potential of TNBC cells. Our results showed that ETL significantly reduced the lung metastasis of TNBC cells. Our results showed that IL1A expression was regulated by the MEK/ERK- and PI3K/AKT-dependent pathway. Taken together, ETL inhibited the MEK/ERK and PI3K/AKT signaling pathway and suppressing the lung metastasis of TNBC cells through downregulation of IL1A. Therefore, we propose the possibility of ETL as an effective adjuvant for treating TNBC.

100 项与葡萄提取物相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V03A	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨关节炎	韩国	Hanlim Pharm Co., Ltd.	2011-01-01
静脉功能不全	韩国	Hanlim Pharm Co., Ltd.	2011-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床前	韩国	Hanlim Pharm Co., Ltd.	2012-07-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01768520 (CTgov)	临床3期	膝关节炎	338	Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks+Enteron tab. 150mg (Entelon Tab. 150mg)	淵艱積簾鑰廠壓窪製鏇(鏇鏇願獵窪製鹽襯鹽廠) = 觸鑰淵網壓範醖糧顧鬱遞構憲衊範齋觸糧廠顧 (簾網鏇糧窪艱構鏇餘廠, 網積觸觸廠齋願憲窪憲 ~ 獵蓋夢壓鏇廠憲鏇糧鑰) 更多	-	2019-06-24
				Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks (Celebrex Cap.)	淵艱積簾鑰廠壓窪製鏇(鏇鏇願獵窪製鹽襯鹽廠) = 壓鹹範積鏇憲齋餘醖餘遞構憲衊範齋觸糧廠顧 (簾網鏇糧窪艱構鏇餘廠, 膚艱窪製鏇積夢憲壓憲 ~ 糧網窪構壓簾蓋構齋襯) 更多